濮阳东方男科医院电话多少濮阳东方医院妇科网络预约,濮阳东方医院做人流手术收费标准,濮阳东方医院治疗早泄咨询,濮阳东方医院做人流手术很好,濮阳东方医院男科治疗阳痿价格非常低,濮阳东方医院看妇科病很不错,濮阳市东方医院医生怎么样

WASHINGTON, Aug. 2 (Xinhua) -- Breastfeeding protects against childhood obesity, but less than 4 percent of U.S. hospitals provide the full range of support mothers need for breastfeeding, according to a report issued by the Centers for Disease Control and Prevention Tuesday.Improving rates of breastfeeding by providing better hospital support to mothers and babies is an important strategy to improve children's health, including a reduced risk of childhood obesity, the monthly Vital Signs report said."Hospitals play a vital role in supporting a mother to be able to breastfeed," it said."Those first few hours and days that a mom and her baby spend learning to breastfeed are critical. Hospitals need to better support breastfeeding, as this is one of the most important things a mother can do for her newborn. Breastfeeding helps babies grow up healthy and reduces health care costs," it added.The report found only 14 percent of hospitals have a written and model breastfeeding policy.It also found in nearly 80 percent of hospitals, healthy breastfeeding infants are given formula when it is not medically necessary, a practice that makes it much harder for mothers and babies to learn how to breastfeed and continue breastfeeding at home.Additionally, only one-third of hospitals practise rooming in, which helps mothers and babies learn to breastfeed by allowing frequent chances to breastfeed.Finally, the report found in nearly 75 percent of hospitals, mothers and babies don't get the support they need when they leave hospitals, including a follow-up visit, a phone call from hospital staff and referrals to lactation consultants, and other important support systems in their communities.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Sept. 6 (Xinhuanet) -- A short-term memory loss may suggest the Alzheimer's disease, according to a new study made by Spanish researchers.The finding was published on Monday, in Archives of General Psychiatry, an American Medical Association journal.The researchers gathered data of 116 people with mild cognitive impairment (MCI) who developed Alzheimer's disease within two years, 204 patients with the condition who didn't develop Alzheimer's and 197 people with no cognitive problems.Mild cognitive impairment is usually marked by difficulties with short-term memory, such as losing your train of thought repeatedly or having trouble remembering what you did yesterday, according to the study.After assessing them by biomarker tests and cognitive measures, the researcher found the cognitive markers can forecast the variance."Remarkably, they accounted for nearly 50% of the predictive variance," said Dr. Gomar of Centro de Investigation Biomedica en Red de Salud Mental, Barcelona, who led the research.Mild cognitive impairment at the start of the study was a stronger predictor of Alzheimer's than most biomarkers, the researchers concluded.

BEIJING, Aug. 12 (Xinhuanet) -- A Connecticut woman who was savagely attacked by a pet chimpanzee and had her face deformed in 2009 was shown on TV with a new face Thursday.TV pictures revealed Charla Nash’s new nose, lips and eyelid, which were transplanted in May by doctors at the Brigham and Women’s Hospital in Boston.Nash said to the viewers that she can move her mouth, smile and smell. Her daughter Brianna added that her mother can even talk and eat better now.Dr. Bohdan Pomanhac led a 30-member surgical team to complete the face transplant in 20 hours. The team also transplanted two hands but these were later removed due to blood flow problem when Nash suffered pneumonia.Nash’s friend Sandra Herold owned a 15-year-old chimpanzee named Travis that attacked without any provocation when Nash was visiting Herold.Travis simply went berserk and could not be stopped even after Herold stabbed it with a kitchen knife. It would only let go of Nash after the police arrived and shot it dead.

BEIJING, Sept. 8 (Xinhuanet) -- Middle-aged white women drinking alcohol moderately are more likely to stay healthy than nondrinkers, according to a new study from Harvard.The study has followed about 14,000 mostly white women since 1976.As a result, compared with teetotalers, those who had 3 to 15 alcoholic drinks weekly in their late 50s were 28 percent higher of being free from physical disability, chronic illness, mental health problems, and cognitive decline at the age of 70.Even having just one or two drinks per week increased a woman's odds of good health by 11 percent.However, women should be aware that even moderate drinking has been linked to an increased risk of breast cancer, said Qi Sun, M.D., a lead author of the study and a nutrition researcher at the Harvard School of Public Health.These findings don't necessarily apply to men or to nonwhite women. But they reinforced the evidence for the health benefits of moderate drinking.